NON-CODING RNA (ncRNA) IN DIABETIC NEPHROPATHY: A REVIEW

Hannie Fitriani; Uzulul Hikmah; Larysa Ferneda; Arba Pramundita Ramadani

doi:10.51771/fj.v5i2.1446

Authors

Hannie Fitriani Universitas Islam Indonesia https://orcid.org/0009-0002-1672-7442
Uzulul Hikmah Universitas Islam Indonesia
Larysa Ferneda Universitas Abdurrab
Arba Pramundita Ramadani Universitas Islam Indonesia

DOI:

https://doi.org/10.51771/fj.v5i2.1446

Keywords:

Diabetes Nefropati, Biomarker, ncRNA

Abstract

Diabetes Nefropati (DN) merupakan penyebab utama terjadinya end‐stage kidney disease. Studi molekuler menunjukkan ncRNA berperan penting dalam mengatur peradangan ginjal, apoptosis, autofagi, proliferasi sel, dan fibrosis ginjal di DN. Pada penelitian ini dilakukan tinjauan artikel mengenai ncRNA sebagai prospek baru dalam pengembangan diagnosis, prognosis, dan pengobatan untuk DN. Metode penelitian dilaksanakan dengan pendekatan studi literatur yang diperoleh dari penelusuran pada database elektronik pubmed dan google scholar dengan kata kunci “ncRNA and diabetes nephropathy” yang mencakup terkait etiologi, patofisiologi, biomarker. ncRNA yang meliputi miRNA, lncRNA, circRNA berperan dalam progresifitas penyakit DN. Studi mengenai ncRNA sebagai terapi masih dalam tahap pengembangan. Miravirsen dan RG-101 adalah beberapa obat miRNA yang telah diuji klinis, tetapi belum ditemukan obat miRNA yang spesifik untuk DN. Salah satu inovasi terapi yang dikembangkan adalah nanopartikel-miRNA-146a-5p (nano-miR-146a-5p) yang menunjukkan aktivitas penekanan ekspresi inflamasi sitokin yang memiliki efek perlindungan yang terjadi melalui regulasi respon inflamasi dan apoptosis. Pengembangan terapi ncRNA pada DN membutuhkan penelitian dan kajian lebih lanjut, sehingga mampu menjadi pilihan pengobatan DN di masa medatang.

References

A/L B Vasanth Rao, V. R., Tan, S. H., Candasamy, M., & Bhattamisra, S. K. (2019). Diabetic nephropathy: An update on pathogenesis and drug development. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 13(1), 754–762. https://doi.org/10.1016/j.dsx.2018.11.054

Alvarez, M. L., & DiStefano, J. K. (2013). Towards microRNA-based therapeutics for diabetic nephropathy. Diabetologia, 56(3), 444–456. https://doi.org/10.1007/s00125-012-2768-x

Cao, Q., Chen, X.-M., Huang, C., & Pollock, C. A. (2019). MicroRNA as novel biomarkers and therapeutic targets in diabetic kidney disease: An update. FASEB BioAdvances, 1(6), 375–388. https://doi.org/10.1096/fba.2018-00064

Chen, X., Zhao, L., Xing, Y., & Lin, B. (2023). Retraction notice to “Down-regulation of microRNA-21 reduces inflammation and podocyte apoptosis in diabetic nephropathy by relieving the repression of TIMP3 expression” [Biomed. Pharmacother. 108 (2018) 7–14]. Biomedicine & Pharmacotherapy, 164, 114725. https://doi.org/10.1016/j.biopha.2023.114725

Choudhury, A., Laskar, R. E., Deka, D., Sonowal, K., Saha, S., & Dey, B. K. (2021). A Review on Nanoparticle: Types, Preparation and its Characterization. Research Journal of Pharmacy and Technology, 14(3), 1815-1822. https://doi.org/10.5958/0974-360X.2021.00322.X

Desai, N., Koppisetti, H., Pande, S., Shukla, H., Sirsat, B., Ditani, A. S., Mallick, P. P., Kathar, U., Kalia, K., & Tekade, R. K. (2021). Nanomedicine in the Treatment of Diabetic Nephropathy. Future Medicinal Chemistry, 13(7), 663–686. https://doi.org/10.4155/fmc-2020-0335

Gomez, I. G., Nakagawa, N., & Duffield, J. S. (2016). MicroRNAs as novel therapeutic targets to treat kidney injury and fibrosis. American Journal of Physiology-Renal Physiology, 310(10), F931–F944. https://doi.org/10.1152/ajprenal.00523.2015

He, X., Kuang, G., Zuo, Y., Li, S., Zhou, S., & Ou, C. (2021a). The Role of Non-coding RNAs in Diabetic Nephropathy-Related Oxidative Stress. Frontiers in Medicine, 8. https://doi.org/10.3389/fmed.2021.626423

He, X., Kuang, G., Zuo, Y., Li, S., Zhou, S., & Ou, C. (2021b). The Role of Non-coding RNAs in Diabetic Nephropathy-Related Oxidative Stress. Frontiers in Medicine, 8. https://doi.org/10.3389/fmed.2021.626423

Huang, X., Zhang, H., Liu, J., Yang, X., & Liu, Z. (2024). Screening candidate diagnostic biomarkers for diabetic kidney disease. Journal of Clinical Laboratory Analysis, 38(3), e25000. https://doi.org/10.1002/jcla.25000

Janssen, H. L. A., Reesink, H. W., Lawitz, E. J., Zeuzem, S., Rodriguez-Torres, M., Patel, K., Meer, A. J. van der, Patick, A. K., Chen, A., Zhou, Y., Persson, R., King, B. D., Kauppinen, S., Levin, A. A., & Hodges, M. R. (2013). Treatment of HCV Infection by Targeting MicroRNA. New England Journal of Medicine, 368(18), 1685–1694. https://doi.org/10.1056/NEJMoa1209026

Kato, M., & Natarajan, R. (2015). MicroRNAs in diabetic nephropathy: Functions, biomarkers, and therapeutic targets. Annals of the New York Academy of Sciences, 1353(1), 72–88. https://doi.org/10.1111/nyas.12758

Kumar, P., Mangla, B., Akthar Imam, S., & Aggarwal, G. (2024). Oral in vivo biodistribution of fluorescent labelled nano lipid carrier system of erlotinib using real time optical imaging technique. International Journal of Pharmaceutics, 664, 124588. https://doi.org/10.1016/j.ijpharm.2024.124588

Liu, B., Cong, C., Ma, Y., Ma, X., Zhang, H., & Wang, J. (2022). Potential value of lncRNAs as a biomarker for proliferative diabetic retinopathy. Eye, 36(3), 575–584. https://doi.org/10.1038/s41433-021-01507-z

Liu, Z., Liu, D., Yang, Y., & Liu, Z. (2022). Noncoding RNAs in diabetic nephropathy. Diabetic Nephropathy, 2(2), 39–51. https://doi.org/10.2478/dine-2022-0016

Loganathan, T. S., Sulaiman, S. A., Abdul Murad, N. A., Shah, S. A., Abdul Gafor, A. H., Jamal, R., & Abdullah, N. (2020). Interactions Among Non-Coding RNAs in Diabetic Nephropathy. Frontiers in Pharmacology, 11. https://doi.org/10.3389/fphar.2020.00191

Luo, Q., Feng, Y., Xie, Y., Shao, Y., Wu, M., Deng, X., Yuan, W.-E., Chen, Y., & Shi, X. (2019). Nanoparticle–microRNA-146a-5p polyplexes ameliorate diabetic peripheral neuropathy by modulating inflammation and apoptosis. Nanomedicine: Nanotechnology, Biology and Medicine, 17, 188–197. https://doi.org/10.1016/j.nano.2019.01.007

Lv, J., Wu, Y., Mai, Y., & Bu, S. (2020). Noncoding RNAs in Diabetic Nephropathy: Pathogenesis, Biomarkers, and Therapy. Journal of Diabetes Research, 2020, 3960857. https://doi.org/10.1155/2020/3960857

Magilnick, N., Reyes, E. Y., Wang, W.-L., Vonderfecht, S. L., Gohda, J., Inoue, J., & Boldin, M. P. (2017). miR-146a–Traf6 regulatory axis controls autoimmunity and myelopoiesis, but is dispensable for hematopoietic stem cell homeostasis and tumor suppression. Proceedings of the National Academy of Sciences of the United States of America, 114(34), E7140–E7149. https://doi.org/10.1073/pnas.1706833114

Maiti, A. K. (2021). Development of Biomarkers and Molecular Therapy Based on Inflammatory Genes in Diabetic Nephropathy. International Journal of Molecular Sciences, 22(18), Article 18. https://doi.org/10.3390/ijms22189985

Papadopoulou-Marketou, N., Kanaka-Gantenbein, C., Marketos, N., Chrousos, G. P., & Papassotiriou, I. (2017). Biomarkers of diabetic nephropathy: A 2017 update. Critical Reviews in Clinical Laboratory Sciences, 54(5), 326–342. https://doi.org/10.1080/10408363.2017.1377682

Paul, P., Chacko, L., Dua, T. K., Chakraborty, P., Paul, U., Phulchand, V. V., Jha, N. K., Jha, S. K., Kandimalla, R., & Dewanjee, S. (2023). Nanomedicines for the management of diabetic nephropathy: Present progress and prospects. Frontiers in Endocrinology, 14. https://doi.org/10.3389/fendo.2023.1236686

Raval, N., Gondaliya, P., Tambe, V., Kalia, K., & Tekade, R. K. (2021). Engineered nanoplex mediated targeted miRNA delivery to rescue dying podocytes in diabetic nephropathy. International Journal of Pharmaceutics, 605, 120842. https://doi.org/10.1016/j.ijpharm.2021.120842

Ree, M. H. van der, Vree, J. M. de, Stelma, F., Willemse, S., Valk, M. van der, Rietdijk, S., Molenkamp, R., Schinkel, J., Nuenen, A. C. van, Beuers, U., Hadi, S., Harbers, M., Veer, E. van der, Liu, K., Grundy, J., Patick, A. K., Pavlicek, A., Blem, J., Huang, M., … Reesink, H. W. (2017). Safety, tolerability, and antiviral effect of RG-101 in patients with chronic hepatitis C: A phase 1B, double-blind, randomised controlled trial. The Lancet, 389(10070), 709–717. https://doi.org/10.1016/S0140-6736(16)31715-9

Rout, P., & Jialal, I. (2025). Diabetic Nephropathy. In StatPearls. StatPearls Publishing. http://www.ncbi.nlm.nih.gov/books/NBK534200/

Samsu, N. (2021). Diabetic Nephropathy: Challenges in Pathogenesis, Diagnosis, and Treatment. BioMed Research International, 2021(1), 1497449. https://doi.org/10.1155/2021/1497449

Simpson, K., Wonnacott, A., Fraser, D. J., & Bowen, T. (2016). MicroRNAs in Diabetic Nephropathy: From Biomarkers to Therapy. Current Diabetes Reports, 16(3), 35. https://doi.org/10.1007/s11892-016-0724-8

Singh, K., Singhal, S., Pahwa, S., Sethi, V. A., Sharma, S., Singh, P., Kale, R. D., Ali, S. W., & Sagadevan, S. (2024). Nanomedicine and drug delivery: A comprehensive review of applications and challenges. Nano-Structures & Nano-Objects, 40, 101403. https://doi.org/10.1016/j.nanoso.2024.101403

Strimbu, K., & Tavel, J. A. (2010). What are biomarkers? Current Opinion in HIV and AIDS, 5(6), 463. https://doi.org/10.1097/COH.0b013e32833ed177

Su, X., Huang, H., Lai, J., Lin, S., & Huang, Y. (2023). Long noncoding RNAs as potential diagnostic biomarkers for diabetes mellitus and complications: A systematic review and meta‐analysis. Journal of Diabetes, 16(2), e13510. https://doi.org/10.1111/1753-0407.13510

Szostak, J., Gorący, A., Durys, D., Dec, P., Modrzejewski, A., & Pawlik, A. (2023). The Role of MicroRNA in the Pathogenesis of Diabetic Nephropathy. International Journal of Molecular Sciences, 24(7), Article 7. https://doi.org/10.3390/ijms24076214

Wang, J., Samuels, D. C., Zhao, S., Xiang, Y., Zhao, Y.-Y., & Guo, Y. (2017a). Current Research on Non-Coding Ribonucleic Acid (RNA). Genes, 8(12), Article 12. https://doi.org/10.3390/genes8120366

Wang, J., Samuels, D. C., Zhao, S., Xiang, Y., Zhao, Y.-Y., & Guo, Y. (2017b). Current Research on Non-Coding Ribonucleic Acid (RNA). Genes, 8(12), Article 12. https://doi.org/10.3390/genes8120366

Zhu, Y., Dai, L., Yu, X., Chen, X., Li, Z., Sun, Y., Liang, Y., Wu, B., Wang, Q., & Wang, X. (2022). Circulating expression and clinical significance of LncRNA ANRIL in diabetic kidney disease. Molecular Biology Reports, 49(11), 10521–10529. https://doi.org/10.1007/s11033-022-07843-x